ubrogepant works by blocking the activity of the CGRP receptors, which transmit pain signals associated with migraines. CGRP is a neuropeptide released during migraine attacks and is believed to play a vital role in the pathophysiology of migraines. By inhibiting the CGRP receptors, ubrogepant helps reduce inflammation and the transmission of pain signals, relieving migraine symptoms.
Spectrum of Activity
It is not intended for preventive therapy or treating other types of headaches. Migraines are characterized by severe headaches often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound.